Smith & Nephew PLC
LSE:SN
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
917.6
1 208.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Smith & Nephew PLC
Smith & Nephew PLC
Depreciation & Amortization
Smith & Nephew PLC
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Smith & Nephew PLC
LSE:SN
|
Depreciation & Amortization
-$192m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
LivaNova PLC
NASDAQ:LIVN
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Angle PLC
LSE:AGL
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Creo Medical Group PLC
LSE:CREO
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Belluscura PLC
LSE:BELL
|
Depreciation & Amortization
-$3.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Smith & Nephew PLC
Glance View
Smith & Nephew PLC has a rich history dating back to 1856, evolving from a small medical supplies company in the UK to a prominent global player in the medical technology industry. The company specializes in advanced wound management, surgical devices, and orthopedic reconstruction, driven by a mission to restore people’s bodies and health, enabling them to live life to the fullest. As an investor, you’ll find that Smith & Nephew stands out for its commitment to innovation, consistently investing a significant portion of its revenue into research and development. This dedication results in a robust pipeline of cutting-edge products, such as its highly regarded advanced wound care solutions and knee and hip reconstruction devices. The company’s strategic focus on emerging markets and partnerships with healthcare providers positions it well for sustainable growth amid shifts in the global healthcare landscape. Navigating the complexities of the healthcare sector, Smith & Nephew demonstrates resilience through its diversified product range and broad geographic presence, generating revenue from both developed and developing markets. The company has been enhancing its operational efficiency, improved profit margins, and reduced costs, which resonate well with value investors seeking financially sound opportunities. Furthermore, the company’s commitment to environmental, social, and governance (ESG) principles may appeal to socially conscious investors. As Smith & Nephew continues to leverage technological advancements and respond to the evolving needs of healthcare systems, its story remains compelling – offering not just potential financial returns but also a commitment to improving patient outcomes and enhancing the quality of life around the globe.
See Also
What is Smith & Nephew PLC's Depreciation & Amortization?
Depreciation & Amortization
-192m
USD
Based on the financial report for Jun 29, 2024, Smith & Nephew PLC's Depreciation & Amortization amounts to -192m USD.
What is Smith & Nephew PLC's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-10%
Over the last year, the Depreciation & Amortization growth was -16%. The average annual Depreciation & Amortization growth rates for Smith & Nephew PLC have been 7% over the past three years , -10% over the past five years .
You don't have any saved screeners yet
